CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+53.29%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$2.09B
AUM Growth
+$2.09B
(+22%)
Cap. Flow
-$302M
Cap. Flow
% of AUM
-14.46%
Top 10 Holdings %
Top 10 Hldgs %
62.94%
Holding
58
New
8
Increased
12
Reduced
13
Closed
10
Top Buys
| 1 |
EyePoint Pharmaceuticals
EYPT
|
$65.6M |
| 2 |
ALX Oncology
ALXO
|
$37.7M |
| 3 |
AUTL
Autolus Therapeutics
AUTL
|
$32.6M |
| 4 |
CRGX
CARGO Therapeutics
CRGX
|
$27.4M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$25.4M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$82.3M |
| 2 |
Structure Therapeutics
GPCR
|
$53.3M |
| 3 |
BridgeBio Pharma
BBIO
|
$53.2M |
| 4 |
CBAY
Cymabay Therapeutics
CBAY
|
$48.4M |
| 5 |
Cabaletta Bio
CABA
|
$43.8M |
Sector Composition
| 1 | Healthcare | 98.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VIGL
51
DELISTED
Vigil Neuroscience
VIGL
| – | – |
-616,786
| Closed | -$3.32M |
|
52
Avidity Biosciences
RNA
$6.12B
| – | – |
-1,762,115
| Closed | -$11.2M |
|
|
53
Structure Therapeutics
GPCR
$1.14B
| – | – |
-1,056,373
| Closed | -$53.3M |
|
54
Erasca
ERAS
$406M
| – | – |
-10,813,246
| Closed | -$21.3M |
|
55
Enliven Therapeutics
ELVN
$1.24B
| – | – |
-1,216,712
| Closed | -$16.6M |
|
56
Editas Medicine
EDIT
$225M
| – | – |
0
| – | – |
|
57
Cogent Biosciences
COGT
$1.83B
| – | – |
-1,000,000
| Closed | -$9.75M |
|
|
58
Cabaletta Bio
CABA
$144M
| – | – |
-2,879,424
| Closed | -$43.8M |
|